| Literature DB >> 30771432 |
Yongmei Feng1, E Hampton Sessions1, Fan Zhang2, Fuqiang Ban2, Veronica Placencio-Hickok3, Chen-Ting Ma1, Fu-Yue Zeng1, Ian Pass1, David B Terry1, Gregory Cadwell1, Laurie A Bankston1, Robert C Liddington1, Thomas D Y Chung1, Anthony B Pinkerton1, Eduard Sergienko1, Martin Gleave2, Neil A Bhowmick3, Michael R Jackson1, Artem Cherkasov2, Ze'ev A Ronai4.
Abstract
Inhibition of ubiquitin ligases with small molecule remains a very challenging task, given the lack of catalytic activity of the target and the requirement of disruption of its interactions with other proteins. Siah1/2, which are E3 ubiquitin ligases, are implicated in melanoma and prostate cancer and represent high-value drug targets. We utilized three independent screening approaches in our efforts to identify small-molecule Siah1/2 inhibitors: Affinity Selection-Mass Spectrometry, a protein thermal shift-based assay and an in silico based screen. Inhibitors were assessed for their effect on viability of melanoma and prostate cancer cultures, colony formation, prolyl-hydroxylase-HIF1α signaling, expression of selected Siah2-related transcripts, and Siah2 ubiquitin ligase activity. Several analogs were further characterized, demonstrating improved efficacy. Combination of the top hits identified in the different assays demonstrated an additive effect, pointing to complementing mechanisms that underlie each of these Siah1/2 inhibitors.Entities:
Keywords: Melanoma; Prostate cancer; Siah1; Siah2; Ubiquitin ligase
Mesh:
Substances:
Year: 2019 PMID: 30771432 PMCID: PMC6411447 DOI: 10.1016/j.canlet.2019.02.012
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679